Concordia Healthcare Corp. (NASDAQ:CXRX) has been given an average rating of “Hold” by the thirteen analysts that are presently covering the company. Two research analysts have rated the stock with a sell rating, five have given a hold rating and five have given a buy rating to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $31.42.

CXRX has been the topic of a number of research reports. RBC Capital Markets reaffirmed an “outperform” rating and issued a $33.00 price target on shares of Concordia Healthcare Corp. in a report on Monday, August 15th. TD Securities reaffirmed a “buy” rating and issued a $37.00 price target (down previously from $45.00) on shares of Concordia Healthcare Corp. in a report on Wednesday, June 29th. Canaccord Genuity cut shares of Concordia Healthcare Corp. to a “buy” rating and set a $10.00 price target on the stock. in a report on Friday, September 16th. CIBC cut shares of Concordia Healthcare Corp. from a “sector perform” rating to an “underperform” rating and set a $7.80 price target on the stock. in a report on Monday, August 15th. Finally, Zacks Investment Research cut shares of Concordia Healthcare Corp. from a “buy” rating to a “hold” rating in a report on Monday, July 18th.

Shares of Concordia Healthcare Corp. (NASDAQ:CXRX) opened at 3.67 on Wednesday. The company’s 50-day moving average price is $5.96 and its 200-day moving average price is $18.48. The firm’s market cap is $187.23 million. Concordia Healthcare Corp. has a 12 month low of $3.64 and a 12 month high of $44.00.

Concordia Healthcare Corp. (NASDAQ:CXRX) last posted its quarterly earnings results on Friday, August 12th. The company reported $1.38 EPS for the quarter, hitting analysts’ consensus estimates of $1.38. The company had revenue of $231.70 million for the quarter, compared to analysts’ expectations of $229.76 million. Concordia Healthcare Corp. had a negative net margin of 81.80% and a positive return on equity of 25.18%. The company’s revenue for the quarter was up 208.1% compared to the same quarter last year. On average, analysts predict that Concordia Healthcare Corp. will post $5.15 EPS for the current year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP purchased a new position in Concordia Healthcare Corp. during the second quarter valued at $2,383,000. UBS Asset Management Americas Inc. boosted its position in Concordia Healthcare Corp. by 64.3% in the second quarter. UBS Asset Management Americas Inc. now owns 27,859 shares of the company’s stock valued at $597,000 after buying an additional 10,900 shares during the last quarter. PNC Financial Services Group Inc. purchased a new position in Concordia Healthcare Corp. during the second quarter valued at $1,855,000. Emerald Acquisition Ltd. purchased a new position in Concordia Healthcare Corp. during the second quarter valued at $1,056,000. Finally, HealthInvest Partners AB purchased a new position in Concordia Healthcare Corp. during the second quarter valued at $11,696,000. 34.01% of the stock is currently owned by hedge funds and other institutional investors.

Concordia Healthcare Corp. Company Profile

5 Day Chart for NASDAQ:CXRX

Receive News & Stock Ratings for Concordia Healthcare Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concordia Healthcare Corp. and related stocks with our FREE daily email newsletter.